BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.5M data for 728K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

21 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Highly Potent and Isoform Selective Dual Site Binding Tankyrase/Wnt Signaling Inhibitors That Increase Cellular Glucose Uptake and Have Antiproliferative Activity.EBI
University of Bath
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.EBI
Health & Science University
Development and structural analysis of adenosine site binding tankyrase inhibitors.EBI
University of Oulu
Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics.EBI
University of Oulu
Towards small molecule inhibitors of mono-ADP-ribosyltransferases.EBI
Karolinska Institutet
Discovery of Quinazoline-2,4(1EBI
Chinese Academy of Medical Sciences and Peking Union Medical College
YCH1899, a Highly Effective Phthalazin-1(2EBI
Shanghai Institute of Materia Medica
[1,2,4]Triazolo[3,4-EBI
University of Oulu
Medicinal Chemistry Perspective on Targeting Mono-ADP-Ribosylating PARPs with Small Molecules.EBI
University of Perugia
Potent 2,3-dihydrophthalazine-1,4-dione derivatives as dual inhibitors for mono-ADP-ribosyltransferases PARP10 and PARP15.EBI
University of Perugia
Rational design of selective inhibitors of PARP4.EBI
Initial Therapeutics
Analogs of TIQ-A as inhibitors of human mono-ADP-ribosylating PARPs.EBI
University of Oulu
Development of a 1,2,4-Triazole-Based Lead Tankyrase Inhibitor: Part II.EBI
Symeres
Preclinical Lead Optimization of a 1,2,4-Triazole Based Tankyrase Inhibitor.EBI
University of Oslo
Discovery and Optimization of 2-Arylquinazolin-4-ones into a Potent and Selective Tankyrase Inhibitor Modulating Wnt Pathway Activity.EBI
Merck Healthcare
Rational Design of Cell-Active Inhibitors of PARP10.EBI
Oregon Health and Science University
4-(Phenoxy) and 4-(benzyloxy)benzamides as potent and selective inhibitors of mono-ADP-ribosyltransferase PARP10/ARTD10.EBI
University of Oulu
Design, synthesis and evaluation of potent and selective inhibitors of mono-(ADP-ribosyl)transferases PARP10 and PARP14.EBI
Mcdaniel College
Discovery of a Novel Series of Tankyrase Inhibitors by a Hybridization Approach.EBI
Leibniz-Forschungsinstitut F�R Molekulare Pharmakologie (Fmp)
Design and synthesis of potent inhibitors of the mono(ADP-ribosyl)transferase, PARP14.EBI
Mcdaniel College
HETEROBIVALENT AND HOMOBIVALENT AGENTS TARGETING FIBROBLAST ACTIVATION PROTEIN ALPHA AND/OR PROSTATE-SPECIFIC MEMBRANE ANTIGENBDB
The Johns Hopkins University